Cancer

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company...

Onco-Innovations Advances Preclinical Program as Nucro-Technics Begins Analytical Development for PNKP Technology

VANCOUVER, BC / ACCESS Newswire / September 29, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased...

Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents

Alleges infringement of three U.S. gene-editing patentsInfringed patents support multiple product pipelines, including Factor's allogeneic cancer cell therapy programsCites need...

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Digital Pathology Market to Surpass US$ 3.86 Billion by 2033 as AI-Enabled Diagnostics and Telepathology Redefine Global Healthcare | DataM Intelligence

AUSTIN, Texas and TOKYO, Sept. 25, 2025 /PRNewswire/ -- The Digital Pathology Market Size reached US$ 1.31 Billion in 2024...

$97M Series D Backed by Strategic Investors Across the Oncology Ecosystem Positions Thyme Care to Break Through Cancer Care’s Biggest Bottlenecks

Thyme Care achieves profitability, manages more than $5B in oncology spend, and extends access to 8M people nationwide in a...

error: Content is protected !!